|
 |
| home > ebr > summer 2003 > biopharmaceutical characterisation - considering key questions |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| In the race to bring new biotech derived products to market, researchers face many obstacles along the road from discovery to commercial success. So, any new analytical techniques which can help smooth the path, particularly through the regulatory approval stages, are always welcome. One such breakthrough has been the use of mass spectrometry (MS) to provide information about the primary protein and carbohydrate structure of biomolecules. MS techniques are now being applied routinely to the characterisation of products ranging in size and complexity from small synthetic peptides to conjugated antibody molecules. However, with the bewildering array of modern analytical instruments available, it is sometimes difficult to choose the most suitable strategies to use for a particular characterisation problem, or indeed decide if or when these studies should be performed. This article intends to address some of the frequently asked questions about biopharmaceutical characterisation using mass spectrometry. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
New PFA SonicLineŽ ultrasonic flowmeters
Flow measurement with ultrasound fast, precise, free from contamination The new PFA SonicLineŽ ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLineŽ is also ideally suited for accurate batch and dosing processes with high reproducibility.
More info >> |
|
 |
